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Martins PJ, Marques MS, Tufik S, D’Almeida V. Orexin acti-
vation precedes increased NPY expression, hyperphagia, and meta-
bolic changes in response to sleep deprivation. Am J Physiol Endo-
crinol Metab 298: E726–E734, 2010. First published January 5, 2010;
doi:10.1152/ajpendo.00660.2009.—Several pieces of evidence sup-
port that sleep duration plays a role in body weight control. Never-
theless, it has been assumed that, after the identification of orexins
(hypocretins), the molecular basis of the interaction between sleep and
energy homeostasis has been provided. However, no study has veri-
fied the relationship between neuropeptide Y (NPY) and orexin
changes during hyperphagia induced by sleep deprivation. In the
current study we aimed to establish the time course of changes in
metabolite, endocrine, and hypothalamic neuropeptide expression of
Wistar rats sleep deprived by the platform method for a distinct period
(from 24 to 96 h) or sleep restricted for 21 days (SR-21d). Despite
changes in the stress hormones, we found no changes in food intake
and body weight in the SR-21d group. However, sleep-deprived rats
had a 25–35% increase in their food intake from 72 h accompanied by
slight weight loss. Such changes were associated with increased
hypothalamus mRNA levels of prepro-orexin (PPO) at 24 h followed
by NPY at 48 h of sleep deprivation. Conversely, sleep recovery
reduced the expression of both PPO and NPY, which rapidly brought
the animals to a hypophagic condition. Our data also support that
sleep deprivation rapidly increases energy expenditure and therefore
leads to a negative energy balance and a reduction in liver glycogen
and serum triacylglycerol levels despite the hyperphagia. Interest-
ingly, such changes were associated with increased serum levels of
glucagon, corticosterone, and norepinephrine, but no effects on leptin,
insulin, or ghrelin were observed. In conclusion, orexin activation
accounts for the myriad changes induced by sleep deprivation, espe-
cially the hyperphagia induced under stress and a negative energy
balance.
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SEVERAL PIECES OF EVIDENCE support that sleep duration plays a
role in body weight control (4, 15, 56). Everson et al. (10),
Kushida et al. (24), and Rechtschaffen et al. (46), using an
animal model, characterized a syndrome induced in response to
sleep deprivation especially composed of a progressive in-
crease in food intake. Interestingly, Spiegel et al. (55) has
shown that humans who are sleep restricted for 2 days (sleep-
ing 4 h/night) were hungrier and developed a craving for food
with a high carbohydrate content. Later, the hyperphagic be-
havior during sleep deprivation was attributed to an increase
and decrease in the hypothalamic expression of neuropeptide Y
(NPY) and proopiomelanocortin (POMC), respectively (20).
Supporting such changes in these neuropeptides, earlier studies
in different species have found a reduction in circulating levels
of leptin in response to sleep loss (11, 22, 55, 56). Although the
described changes in the neuropeptides and leptin levels of
sleep-deprived animals agreed with the current model of body
weight control (48), the main concern of this explanation for
hypothalamic neuropeptide changes induced by sleep depriva-
tion is the large weight loss at the time in which leptin was
measured. Leptin is released by adipocytes in response to
changes in the energy balance, providing the brain information
about energy (fat) stores (17). Recently, we showed that
chow-fed rats present with an impaired food intake during the
early days of sleep deprivation, which leads to large weight
loss (30, 31). In addition, the weight loss observed in sleep-
deprived rats on the chow diet was accounted for mainly by a
reduction of adipose tissue (39). Therefore, it is unknown whether
reduced leptin levels are the major regulator of the hypothalamic
neuropeptide changes and, consequently, the hyperphagia during
sleep deprivation since the previous studies assessed the leptin
levels only after days of reduced weight (11, 22).
The previous descriptions of increased food intake and
energy expenditure in response to sleep deprivation (3, 22), as
well as the fasting-feeding cycle modulation of sleep allocation
(37), reinforce the interconnection between the energy ho-
meostasis process and sleep control. However, only after the
identification of hypothalamic neuropeptides named orexins
(or hypocretins) was the molecular basis of the interaction
between sleep and energy homeostasis control provided (57).
Initially, the orexins (orexin A and orexin B) were recognized
as feeding behavior regulators due to their production in the
lateral hypothalamus (previously known as the feeding center)
and their pharmacological activity (9, 47). Later, the orexins
were shown to have a role in the maintenance of wakefulness,
as demonstrated by the association of orexin signaling defi-
ciencies and the sleep disorder narcolepsy (6, 26). Thereafter,
evidence that fasting and sleep deprivation increase both NPY
and the orexin precursor, prepro-orexin (PPO), mRNA levels
in the hypothalamus of rats (20, 45, 47) supported the interac-
tion of these peptides in the control of feeding and sleep
behaviors. Although it has been hypothesized that the in-
creased appetite observed during the sleep deprivation is a
condition that might involve orexin activation (19, 20), no
study has verified the relationship between NPY and orexin
changes in regard to the hyperphagia induced by the sleep
deprivation. Knowing that in the hypothalamus there are sev-
eral hormonal and nutrient signals from the periphery that are
sensed and integrated to allocate the appropriate behavior and
physiological response to maintain the energy homeostasis (16,
48), the present study was conducted to establish the time
course of changes in metabolite, endocrine, and hypothalamic
neuropeptide expression associated with hyperphagia induced
by sleep deprivation.
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METHODS
Animals, housing conditions, and ethical care. Male Wistar rats
from a colony maintained by the Psychobiology Department of the
Federal University of São Paulo were employed. These animals were
derived from the Charles River Laboratories (Wilmington, MA)
foundation colony. During the experiment, all animals were kept on a
12:12-h light-dark cycle (lights on at 0700) under controlled temper-
ature (21–24°C) conditions and with free access to food and water.
Animal care and use procedures were carried out by trained personnel
(FELASA Category C) and conducted in accordance with the Na-
tional Research Council Guide for the Care and Use of Laboratory
Animals. The experimental protocol was approved by the Ethics
Committee of the Federal University of São Paulo [Comitê de Ética
em Pesquisa (CEP; Research Ethical Committee) no. 0064/01].
Sleep deprivation procedure. The sleep deprivation procedure used
was the classical platform method, which consists of placing one
animal on top of a narrow platform (6.5 cm in diameter) surrounded
by water in a 23 23 35 cm container [for details, see Martins et al.
(30)]. Previous data from our laboratory show that the platform
method results in a complete reduction of paradoxical sleep and a 37%
decrease in slow-wave sleep (27). All animals were allowed to adapt
to the platform for 30–40 min for 3 consecutive days, and sleep
deprivation was started at 0800 after 1 day of washout. The control
group animals were put individually into the same container as the
sleep-deprived animals, but the water was substituted by wood paring.
This substitution was also performed during the rebound period in the
recovered group.
Experimental protocol. Seven days before the experiment, male
rats were housed individually and adapted to consume a balanced
liquid diet. The liquid diet (cat. no. F1268; Bio-Serv, Frenchtown, NJ)
was delivered by liquid diet feeding tubes (cat. no. 9011; Bio-Serv)
and was accessible during all experiments from wall feeders. The
liquid diet differs only slightly from chow, and its caloric profile was
20.8% of the calories derived from protein, 11.9% from fat, and
67.3% from carbohydrates, providing a total of 1.0 kcal/ml. Thereaf-
ter, seven groups were established. In four of the groups, the rats were
continuously sleep deprived for 24 (SD-24h), 48 (SD-48h), 72 (SD-
72h), and 96 h (SD-96h), whereas another group of rats were kept
under the control condition (CT). The last two groups were composed
of rats that were 96-h sleep deprived and permitted to sleep for 24 h
(RB-24h) and rats that were sleep deprived daily from 4 PM to 10 AM
(sleep ad libitum from 10 AM to 4 PM) over 21 days before sample
harvesting (SR-21d), as described previously elsewhere (28). The
samples from the control group were harvested on the same day as the
RB-24h. Body weight and food intake were recorded daily between
0700 and 0800. Animals of each group were euthanized randomly by
decapitation between 0800 and 0900 for tissue sample collection.
Analytical procedures. Blood aliquots were collected in tubes
containing prechilled disodium fluoride, EDTA, and either heparin or
no anticoagulant (Becton-Dickinson). Tubes were centrifuged at 4°C
for 10 min at 3,000 rpm to extract plasma and serum aliquots,
respectively. A set of serum aliquots were stored at80°C for insulin,
glucagon, leptin, adiponectin, ghrelin (Linco Research, St. Louis,
MO), and corticosterone measurements (ICN-Biomedical, Orange-
burg, NY) using RIA kits. Immediately after collection, plasma and
another set of serum aliquots were used for glucose, total cholesterol,
high-density lipoprotein (HDL) cholesterol, and triacylglycerol deter-
mination using colorimetric automated procedures (ADVIA 1650;
Bayer Diagnostics) routinely performed in clinical laboratories. To
measure ketone bodies, deproteinized supernatants were obtained by
collecting blood aliquots in perchloric acid (1 M) and then centrifuged
at 4°C for 20 min at 3,400 rpm. Deproteinized supernatants were used
to determine acetoacetate and -hydroxybutyrate concentrations spec-
trophotometrically (5) immediately after the collection. Liver samples
were rapidly excised, weighed, and maintained in potassium hydrox-
ide (30%) solution until glycogen storage was measured by sulphuric
acid anthrone reaction (49) on the same day of euthanization.
Tissue preparation and real-time PCR. The hypothalamus was
dissected on the basis of anatomic landmarks. Briefly, the brains were
placed ventral side up, and the whole hypothalamus was scooped out
with a dissecting microspatula using the optic chiasm as the anterior
boundary, the medial mammillary body as the posterior boundary, and
the lateral edge of the hypothalamus at the border of the pyriform
lobes as the lateral boundary. Following the dissections, Trizol re-
agent (Invitrogen, Carlsbad, CA) was added to the hypothalamus and
total RNA isolated according to the manufacturer’s protocol. An
agarose gel (1%) electrophoresis was done to evaluate the integrity of
the molecule. After DNAse (Promega) treatment, total RNA was
reverse transcribed using ImProm-IITM Reverse Transcriptase (Pro-
mega). Diluted cDNA were added to 2 SYBR Green PCR Master
Mix (Applied Biosystems, Warrington, UK) and the respective prim-
ers for PPO, NPY, POMC, agouti-related protein (AgRP), and mel-
anin-concentrating hormone (MCH) (Table 1). The expression of
target genes was normalized using 1-tubulin as the endogenous
control. Quantitative real-time PCR assays were performed using
96-well plates sealed with optical quality film (Applied Biosystems)
on an Opticon-2 Real-Time PCR Detection System (MJ Research;
incorporated by Bio-Rad Laboratories). The analysis of relative ex-
pression was performed using a standard dilution curve-based method
for relative real-time PCR data processing performed on a Microsoft
Excel spreadsheet (25). Results were expressed in arbitrary units.
Statistical analysis. Results are presented as means  SE. A
two-way ANOVA for repeated measurements was performed to
analyze the effects of sleep loss on body weight and food intake pre-
and postdistinct sleep deprivation periods. For the metabolites, hor-
mones, and gene expression parameters, we performed a one-way
ANOVA. All ANOVAs were followed by Duncan’s multiple range
tests and with an -value set at 0.05.
RESULTS
In Fig. 1, we present the changes in the body weight of rats
sleep deprived for different periods of time. As described
previously, there was only a slight weight loss after 48 h of
sleep deprivation, which remained reduced after 24 h of recov-
ery [ANOVA interaction factor F(6,60)  9.32, P  0.0001].
Table 1. Primer sequences used in quantitative PCR
reactions
Gene Primers
1-Tubulin
Sense 5=-TACCCTCGCATCCACTTCCCT-3=
Antisense 5=-CGCTTGGTCTTGATGGTGGCA-3=
NPY
Sense 5=-GCGACACTACATCAATCTCATC-3=
Antisense 5=-AAGGGTCTTCAAGCCTTGTTC-3=
POMC
Sense 5=-CGAGATTCTGCTACAGTCGCTCA-3=
Antisense 5=-TTCATCTCCGTTGCCTGGAAACAC-3=
PPO
Sense 5=-AGAAGACGTGTTCCTGCCGT-3=
Antisense 5=-CGTGGTTACCGTTGGCCTGAA-3=
AgRP
Sense 5=-CTGCTGCAGAAGGCAGAAGC-3=
Antisense 5=-GAAGAAGCGGCAGTAGCACGG-3=
MCH
Sense 5=-TTCCCAGCTGAGAATGGAGTTCAG-3=
Antisense 5=-CCCAGCATACACCTGAGCATGTC-3=
NPY, neuropeptide Y; POMC, proopiomelanocortin; PPO, prepro-orexin;
AgRP, agouti-related protein; MCH, melanin-concentrating hormone.
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On the other hand, the body weight of the control group
animals increased during this period (Fig. 1).
Surprisingly, earlier than described previously by Everson
et al. (10), Kushida et al. (24), Rechtschaffen et al. (46), and
Koban and colleagues (20–22), we found that rats fed a liquid
diet had a 25–35% increase in their food intake after 72 and 96
h of sleep deprivation [ANOVA interaction factor F(6,60) 
8.80, P  0.0001]. During the recovery period the rats con-
sumed significantly less liquid diet compared with presleep
deprivation consumption (Fig. 2). Interestingly, our protocol of
21 days of sleep restriction did not change body weight or food
intake (Figs. 1 and 2).
We assessed the gene expression of hypothalamic neuropep-
tides involved in the control of both food intake and sleep.
Despite the fact that there was no change in the expression of
AgRP [F(6,60)  1.34, P  0.25], the expression of NPY was
increased from 48 up to 96 h of sleep deprivation, supporting
the observed changes in the food intake, whereas recovery and
sleep-restricted groups were similar to the control animals
[F(6,60) 4.85, P 0.001] (Fig. 3, A and B). As expected, PPO
gene expression was increased from 24 up to 96 h of sleep
deprivation, but it was reduced to the control levels after the
recovery period [F(6,60)  5.36, P  0.0001; Fig. 3C]. Inter-
estingly, not only did chronically sleep-restricted rats have a
higher expression of PPO, but MCH was also increased [F(6,60) 
2.33, P  0.042; Fig. 3D], and POMC gene expression was
reduced [F(6,60)  3.30, P  0.043; Fig. 3E].
Despite a slight reduction in insulin levels [F(6,60)  3.07,
P  0.01; Fig. 4] after 96 h of sleep deprivation there were no
statistical differences compared with the control group. There
was also no effect on the serum levels of leptin [F(6,60)  1.70,
P  0.13] or ghrelin [F(6,60)  1.81, P  0.11] after different
periods of sleep deprivation or after 21 days of sleep restriction
(Fig. 4, A, C, and D). However, we found that continuous sleep
deprivation had an increasing effect on serum glucagon levels,
which were increased significantly in the 48- to 96-h sleep
deprivation groups [F(6,60)  6.29, P  0.0001], but the levels
were similar to the control group after 24 h of recovery (Fig.
4B). Adiponectin levels were also changed [F(6,60) 3.10, P
0.01], showing a significant reduction after 72 h of sleep
deprivation (Fig. 4E).
Stress response hormones were also distinctly modified by
the sleep disturbance protocols. Regarding home cage control,
corticosterone [F(6,60)  10.99, P  0.001] levels were in-
creased significantly from 24 h and norepinephrine levels
[F(6,60)  6.25 P  0.001] during 48–96 h of sleep depriva-
tion, but 24 h of recovery was sufficient to reverse the changes
in both hormones (Fig. 5, A and B). The sleep-restricted group
showed no changes in serum glucagon levels; however, corti-
costerone, epinephrine [F(6,60)  4.56, P  0.01], and norepi-
nephrine levels were increased (Fig. 5, A–C).
In accord with our previous observations, sleep deprivation
reduced liver glycogen stores. In the present experiment we
found that, during 24–96 h of continuous sleep deprivation, the
liver glycogen content was reduced [F(6,60)  6.33 P 
0.0001]. Nevertheless, after 24 h of recovery, the liver glyco-
gen store was still lower than that observed in the control
group, although 21 days of sleep restriction did not change the
levels (Fig. 6).
Likely due to glycogen breakdown, no effects of sleep depri-
vation on circulating glucose [F(6,60) 1.09, P 0.42] or ketone
body levels [F(6,60)  0.60, P  0.72] were found (Fig. 7, A and
B). ANOVA revealed the effects of different sleep deprivation
periods on the total cholesterol [F(6,60) 2.67, P 0.02], HDL
cholesterol [F(6,60)  3.50, P  0.01], and triacylglycerol
[F(6,60) 4.53, P 0.001] levels (Fig. 7, C–E). However, post
hoc comparison revealed only that triacylglycerol levels were
reduced compared with the control group during 48–96 h of
continuous sleep deprivation (Fig. 7E). Therefore, no effects of
sleep deprivation or restriction on the blood levels of total
cholesterol and HDL cholesterol were found.
DISCUSSION
In this study, we have shown that the hyperphagia induced
during the sleep deprivation of rats on a liquid diet starts earlier
than described previously for rats on a chow diet deprived by
disk-over-water (10, 24) or platform (22, 30) use. This differ-
ence is likely due to an easier access of food. Consequently,
unlike rats on only a chow diet, a slight reduction in body
weight was noticed during 48–96 h of sleep deprivation (Fig.
1). Of even greater importance is that during the recovery
period the sleep rebound blunted the hunger, and despite lower
body weight the food intake was reduced to a level below that
which was recorded before (pre) sleep deprivation (Figs. 1 and
2). Surprisingly, no effects on food intake or body weight were
observed in the rats that were sleep restricted for 21 days (Figs.
1 and 2). Together, these data suggest that, rather than a
counterregulation response to weight loss, hyperphagia in rats
Fig. 2. Food intake (means  SE) by rats pre- (open bars) and post-sleep
deprivation (closed bars) for SD-24h, SD-48h, SD-72h, and SD-96h; RB-24h,
SR-21d, and CT rats. *Different from respective pre-sleep deprivation using
Duncan’s test, P  0.05.
Fig. 1. Body weight (means SE) of rats pre- (PRE; open bars) and post-sleep
deprivation (POST; closed bars) for 24 (SD-24h), 48 (SD-48h), 72 (SD-72h),
and 96 h (SD-96h); 24-h rebound (RB-24h), 21 days of sleep restriction
(SR-21d), and control (CT) rats. *Different from respective pre-sleep depri-
vation using Duncan’s test, P  0.05.
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can be a consequence of activating the feeding centers by
prolonged wakefulness.
Indeed, Koban et al. (20) have shown that sleep deprivation
increased the expression of the most potent orexigenic peptide,
NPY, and reduced the anorexigenic peptide POMC in the
hypothalamus of rats. Such changes have been attributed to a
reduction in the leptin levels observed after 5 or more days of
sleep deprivation (11, 22). Nevertheless, long-term sleep de-
privation of rats on a chow diet induces large weight loss,
especially through the reduction of adipose tissue (39), which
can account for the reduced serum leptin levels. In such cases,
increased NPY and the consequent hyperphagia should be a
response to weight loss rather than an effect of the sleep
deprivation itself. However, more recently, Koban et al. (21)
have shown that rats receiving Ensure, a human liquid diet,
developed hyperphagia after 6 days of sleep deprivation, and
body weight changes were greatly minimized. Therefore, if the
body weight of rats on a liquid diet was only slightly modified
by sleep deprivation, it is possible that the changes in the serum
leptin levels might also be different from those reported for rats
on chow diet. Unfortunately, the leptin levels were not reported
in the previous studies of rats sleep deprived on a liquid diet
(14, 21). However, in the present study we show that through
96 h of sleep deprivation the weight loss of rats on a liquid diet
was 4%, and there were no significant changes in the serum
levels of insulin, leptin, and ghrelin (Fig. 4, A, C, and D,
respectively). The absence of changes in serum leptin levels is
reinforced by no changes in white adipose tissue leptin mRNA
levels (data not shown). Therefore, since the sleep deprivation
of rats on a liquid diet leads to increasing food intake (Fig. 2)
and NPY hypothalamic expression (Fig. 3A) but no changes in
the major hormones associated with the control of its expres-
sion, including leptin (Fig. 4), we believe that other factors
linked directly to the sleep deprivation should be determinant
for this type of hyperphagia.
The expression of NPY in the hypothalamus occurs espe-
cially in a population of neurons of the arcuate nucleus and is
colocalized with another orexigenic peptide, AgRP. We veri-
Fig. 3. Hypothalamic mRNA levels (means SE) of
neuropeptide Y (NPY; A), agouti-related peptide
(AgRP; B), prepro-orexin (PPO; C), melanin-con-
centrating hormone (MCH; D), and proopiomelano-
cortin (POMC; E) after SD-24h, SD-48h, SD-72h,
and SD-96h; RB-24h, SR-21d, and CT rats. *Differ-
ent from control group using Duncan’s test, P 
0.05.
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fied that NPY mRNA levels were elevated significantly from
48 to 96 h of sleep deprivation (Fig. 3A), but despite its
colocalization, no significant changes in AgRP expression
were found (Fig. 3B). Interestingly, the arcuate nucleus re-
ceives projections from the lateral hypothalamus area, where
two other peptides, the orexins and MCH, which are linked to
food intake and sleep control, are produced (43). We found that
mRNA levels of the peptide precursor of orexins, PPO, were
higher during 24–96 h of sleep deprivation (Fig. 3C), whereas
no change in MCH was observed (Fig. 3D). The temporal
organization of these events suggests that increased orexinergic
activity during sleep deprivation activates arcuate NPY neu-
rons, consequently leading to the hyperphagia observed from
72 h of sleep deprivation. There is numerous evidence to
support such a hypothesis of interaction between orexins and
NPY on the hyperphagia induced by sleep deprivation, includ-
ing the fact that arcuate injection of orexins increases food
intake (35). Also, orexin neurons project densely into the
arcuate nucleus (36), and both orexin receptors (OX1R and
OX2R) are also expressed in this nucleus (8). In addition,
central administration of orexin increases Fos expression (61)
and electrical activity (59) of the arcuate NPY neurons. Fur-
thermore, the orexigenic effects of intracerebroventricular (icv)
administration of orexin-A can be inhibited partly by a
NPY-Y1 receptor antagonist (18).
In rodents, the orexinergic system seems to respond quickly
to modifications in the sleep-wake cycle, increasing both the
concentration of orexin-A in cerebrospinal fluid and hypotha-
lamic mRNA levels after 6–8 h of sleep deprivation (42, 45).
Furthermore, 24 h of sleep recovery reduced the higher cere-
brospinal fluid levels of orexin-A observed after 96 h of sleep
deprivation to levels below that of the control animals (42). On
the other hand, a single or daily icv administration of orexin
only increases food intake during the first hours postadminis-
tration and has no effect on 24-h food intake (50, 62). To-
gether, these data suggest that orexin has a short-term effect,
Fig. 4. Serum levels (means  SE) of insulin (A),
glucagon (B), leptin (C), ghrelin (D), and adiponectin
(E) after SD-24h, SD-48h, SD-72h, and SD-96h; RB-
24h, SR-21d, and CT rats. *Different from control
group using Duncan’s test, P  0.05.
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and so a tonic action of the orexins sustained by the continuous
sleep deprivation is required to consequently increase NPY
expression and 24-h food intake. This could explain the ab-
sence of changes in NPY expression and food intake of
sleep-restricted rats despite changes in PPO gene expression
(Fig. 3, A and C). It is important to notice that the effects of
chronic sleep restriction were assessed at 1–2 h before the
beginning of the sleep window (supposed to occur from 10 AM
to 4 PM). Therefore, a higher PPO expression is expected due
to the previous extended period of wakefulness. Yet this was
not enough time to increase NPY expression, which seems to
require 48 h of sleep deprivation to be increased (Fig. 3A). In
accord with that, we also observed that sleep had a powerful
effect to reverse not only PPO but also NPY expression (Fig.
3, A and C), which rapidly brought the animals from a hy-
perphagic to hypophagic condition (Fig. 2). It is possible that
the hypophagia observed during the sleep recovery is due to an
increased sleep time after the forced sleep loss, also referred to
as a sleep rebound. Using our protocol of sleep deprivation, it
has been shown that following 96 h of sleep deprivation the
awake time of rats was reduced, whereas the sleep time was
increased during the initial 24 h of recovery, especially due to
an increase in paradoxical sleep (27). Since the animals were
free to express both feeding and sleep behaviors during the
recovery period, it is possible that during the recovery period
the sleep mechanisms overcome the hunger mechanisms, con-
sequently reducing food intake. However, if that was the case,
we would expect that the NPY expression be kept high, if not
higher, after a hypophagic sleep recovery period. Hence, we
assume that the continuous orexin activation induced by the
sleep deprivation increases NPY expression, whereas periods
of sleep prevented or reversed it. Modirrousta et al. (32) have
proposed that orexin neurons may act to sustain waking during
sleep deprivation, whereas MCH neurons may act to promote
sleep following sustained waking. Therefore, the increased
expression of PPO and MCH observed in the sleep-restricted
animals (Fig. 3, C and D, respectively) may be explained by
the recurring cycle of extended waking/consolidated sleep
experienced during the 21 days (28). Indeed, orexin action in
the arcuate nucleus seems to not only increase NPY neuron
activity but also reduce that of POMC neurons (35). In our
experiment, the expression of POMC did not change through
the 96 h of sleep deprivation, but it was reduced after 21 days
of sleep restriction. Our data agree with the previous observa-
tions that the inhibitory effect of POMC on arcuate expression
occurred only at 20 days of sleep deprivation (20). However,
21 days of sleep restriction failed to induce hyperphagia, which
suggests that reduction of POMC expression is not required for
the hyperphagia associated with sleep deprivation. One could
argue that the sleep restriction protocol did not reduce sleep,
but it has been shown previously that this protocol reduces total
sleep time, especially paradoxical sleep, throughout the 21
days of restriction, whereas a sleep debit was reinforced by the
sleep rebound during 48 h of recovery (29).
Increased glucocorticoid profiles are known to be present in
subjects submitted to experimental sleep loss (53, 54). Like-
wise, sleep loss has been associated with higher levels of
ACTH and glucocorticoids in rats (2, 3, 39). Following the
observed changes in PPO mRNA during the sleep deprivation,
we observed that corticosterone and norepinephrine levels
were increased at 24 and 48 h of sleep deprivation, respectively
(Fig. 5, A and B). Indeed, previous studies have described
Fig. 6. Liver glycogen concentration (means  SE) after SD-24h, SD-48h,
SD-72h, and SD-96h; RB-24h, SR-21d, and CT rats. *Different from control
group using Duncan’s test, P  0.05.
Fig. 5. Serum levels (means  SE) of corticosterone (A), norepinephrine (B),
and epinephrine (C) after SD-24h, SD-48h, SD-72h, and SD-96h; RB-24h,
SR-21d, and CT rats. *Different from control group Duncan’s test, P  0.05.
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increased corticotropin-releasing hormone (CRH) expression
in the paraventricular nucleus (PVN) of sleep-deprived rats
(12, 20). Several lines of evidence support that orexinergic
activation mediates sympathetic and hypothalamus-pituitary-ad-
renal axis activation during sleep deprivation. Administration of
orexins into the cerebral ventricles quickly increased plasma
ACTH and subsequently corticosterone levels in a dose-response
fashion (13, 23). Such effects were explained by the activation of
the PVN, as demonstrated by increased c-fos (23) and CRH
mRNA levels (1). Intriguingly, the effect of orexins on the
hypothalamus-pituitary-adrenal axis is independent of its effects
on NPY neurons (34). Therefore, except for no changes in NPY
expression after 21 days of sleep restriction, rats showed the
highest PPO expression and increases not only in norepinephrine
but also epinephrine levels (Fig. 3, B and C). These response
profiles also agree with the previous observation that icv injec-
tions of orexin increased plasma levels of norepinephrine and
epinephrine at lower and higher doses, respectively (52).
Such sympathetic activation in response to high orexin
activity might also be related to other metabolic and hormonal
changes observed during the sleep deprivation. Spiegel and
colleagues (53, 54) have shown elevations of the sympathova-
gal balance in response to sleep loss. In addition, increased
sympathetic activity of the splenic nerve is classically associ-
ated with increased release of glucagon by the -cells of the
pancreas (58). This is in accord with the observation that
glucagon concentration was increased in animals deprived
from 48 to 96 h but was not changed in animals sleep restricted
for 21 days (Fig. 4B). Glucocorticoids and catecholamines also
have important effects on glycogen metabolism; however, liver
glycogen (Fig. 6) was not changed in sleep-restricted animals
despite their higher levels of corticosterone, norepinephrine,
and epinephrine (Fig. 5). Therefore, it is likely that the glyco-
gen reductions described in the present study (Fig. 6) were
directed by increases in glucagon levels induced by sleep
deprivation (Fig. 4B). In addition, such changes in the gluca-
Fig. 7. Blood levels (means  SE) of glucose (A),
ketone bodies (B), total cholesterol (C), high density
lipoprotein (HDL) cholesterol (D), and triacylglycerol
(E) after SD-24h, SD-48h, SD-72h, and SD-96h; RB-
24h, SR-21d, and CT rats. *Different from control
group using Duncan’s test, P  0.05.
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gon levels are consistent with the observed changes of NPY
expression in the hypothalamus (Fig. 3A). Together, these data
suggest that the tonic action of orexins on arcuate NPY neurons
might lead to increased glucagon secretion and reduced liver
glycogen. In agreement with such an idea, previous studies
have shown that icv injection of either NPY or orexin-A
increases circulating glucagon levels (40, 41). However, addi-
tional experiments are needed to fully prove this hypothesis.
In opposition to other orexigenic peptides, the orexins in-
crease energy expenditure (50), which seems to occur through
thermogenesis and/or locomotor activity. Intra-arcuate injec-
tions of orexin-A in anesthetized rats increased oxygen con-
sumption (V˙ O2) and body temperature (60). On the other hand,
daily intra-PVN injection of orexin-A increased locomotor
activity with no change in food intake (38). In agreement with
these orexin effects, besides hyperphagia, weight loss and
increased energy expenditure have been shown in rats under-
going prolonged sleep deprivation by different procedures (3,
22). This high-energy expenditure has been explained by the
increased activity of uncoupling proteins in the liver, skeletal
muscle, and brown adipose tissue (7, 22). Additionally, it is
well known that sympathetic activation under higher energy
demand is responsible for increased fatty acid contribution as
an energy source. For instance, activation of the ventromedial
nucleus accelerates the turnover of triacylglycerols, which in-
creases the production of heat through uncoupling proteins in
brown adipose tissue (51). In the same way, icv injection of orexin
increased body temperature and the firing rate of the sympathetic
nerves to the interscapular brown adipose tissue but was blunted
after the ventromedial nucleus of the hypothalamus was damaged
(33). In this sense, although we found no changes in the blood
levels of glucose, ketone bodies, and cholesterol lipoproteins,
there was a progressive reduction in serum triacylglycerols during
the sleep deprivation (Fig. 7), suggesting that sleep deprivation
quickly increases energy expenditure and fatty acid utilization
likely though a thermogenic process.
Interestingly, opposed metabolic repercussions have been
observed in narcoleptic patients with cataplexy, which were
associated with impaired orexin function by lower cerebrospi-
nal fluid orexin-1 levels compared with a well-matched control
group with idiopathic hypersomnia. Narcoleptic patients, de-
spite consuming 15% less calories daily, had higher body and
fat mass as well as circulating levels of leptin and triacylglyc-
erols, among other metabolic abnormalities. Altogether, these
data suggest that the implication of the orexinergic system on
metabolism seems to go beyond the food intake and energy
expenditure and may involve specific actions on glucose and
lipid metabolism control (44). In summary, based on our
results, 3 days of continuous sleep deprivation are sufficient to
trigger hyperphagia in rats fed a liquid diet. Although several
parameters, such as food composition/palatability and accessi-
bility, are important to establish how much food is consumed
during the sleep deprivation, it is most likely that the daily
amount of sleep lost determines the onset of hyperphagia.
However, this mechanism seems to be complex and requires a
tonic action of the orexins on NPY neurons that is likely to
overcome the anorectic effects of CRH that can also be
activated by the orexins during sleep deprivation. Our present
data suggest that orexin activation explains a myriad of
changes induced by sleep deprivation, especially hyperphagia
under stress and the negative energy balance.
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